Alnylam Pharmaceuticals Inc. (ALNY) faced a significant drop in its stock price amid market volatility and investor concerns.
Alnylam Pharmaceuticals Inc. experienced a notable decline in its stock price, closing down 1.34% at CA$250.66. This downturn comes as the company continues to navigate challenges in the competitive RNA therapeutics landscape.
Investor takeaway: Investors should be cautious as Alnylam's recent performance reflects broader market uncertainties and potential concerns regarding its growth trajectory in the RNA therapeutics sector.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$34.17B
P/E
44.6x
52W high
$495.55
52W low
$197.81
1W change
+0.96%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 46.2% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+46.2% Upside
Current Price
C$254.07
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.7%
Annualized
90-Day Vol
76.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$212.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$239.39 | C$204.47 – C$280.27 |
| 60 trading days | C$225.55 | C$180.47 – C$281.90 |
| 90 trading days | C$212.52 | C$161.73 – C$279.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Alnylam's innovative RNAi therapeutics and strong sales growth of its flagship product, AMVUTTRA, position it well for future success. As awareness and diagnosis of ATTR-CM improve, the company could see increased demand for its treatments.
Bear case
The recent stock decline highlights investor skepticism about Alnylam's ability to maintain momentum in a crowded market. With potential competition and regulatory challenges ahead, investors may worry about the company's growth prospects.
Advertisement
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
